Skip to main content
Premium Trial:

Request an Annual Quote

Filing Regulations Force Orchid to Delays Q4 and 2005 Reports

NEW YORK, March 30 (GenomeWeb News) - Orchid Cellmark will delay the filing of its fourth-quarter and full-year 2005 earnings reports with the US Securities and Exchange commission due to audit requirements associated with the Sarbanes-Oxley Act of 2002.

 

Orchid originally planned to issue financial results on March 30, and the firm intends to announce a new date "as soon as possible," according to the statement.

 

The legislation, which opponents call costly and complex, has caused several small publicly traded companies to delay their recent filings, though the SEC has generally allowed this. Supporters say it can protect investors and employees from corporate fraud.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.